220,800 Shares in Pfizer Inc. $PFE Purchased by OPTIMAS CAPITAL Ltd

OPTIMAS CAPITAL Ltd acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 3rd quarter, Holdings Channel reports. The fund acquired 220,800 shares of the biopharmaceutical company’s stock, valued at approximately $5,626,000. Pfizer accounts for about 3.6% of OPTIMAS CAPITAL Ltd’s investment portfolio, making the stock its 12th largest holding.

Other large investors have also bought and sold shares of the company. Curio Wealth LLC boosted its position in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. bought a new position in Pfizer during the 2nd quarter valued at about $29,000. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer in the second quarter worth approximately $30,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Stock Performance

Shares of PFE opened at $27.24 on Monday. The business has a 50-day simple moving average of $25.61 and a two-hundred day simple moving average of $25.10. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The stock has a market cap of $154.88 billion, a price-to-earnings ratio of 20.03 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the company posted $0.63 EPS. The firm’s revenue was down 1.2% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.